News

All eyes are on Alnylam as the company awaits entry into the transthyretin amyloid cardiomyopathy market, which currently includes Pfizer and BridgeBio and is…

AbstractClinical genetic testing often takes days to weeks, but rapid, affordable tests during outpatient visits could significantly benefit patients. This is…

"More than a century ago, Dr. Alois Alzheimer described the brain changes in a younger woman who had passed away from what we now call Alzheimer's disease,"…

CNBC’s Angelica Peebles talks to Alnylam CEO Yvonne Greenstreet about the new administration, what to expect in 2025 and the latest on their ATTR-Cardiomyopathy…

AbstractPurpose of Review The most common type of cardiac amyloidosis is transthyretin amyloidosis (ATTR-CM). Early forms of the disease can often go undetected.…

“The symptoms are sometimes vague and they often mimic other conditions like cancer, neuropathic conditions and heart disease,” says Dr. Keyur Shah.Abnormal…

Alnylam Pharmaceuticals, Inc., an American company at the forefront of innovation, today received the 2024 Tell Award from Ambassador Niculin Jaeger, Consul General…

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its preliminary* fourth…